Impact of kinase activating and inactivating patient mutations on binary PKA interactions.
The second messenger molecule cAMP links extracellular signals to intracellular responses. The main cellular cAMP effector is the compartmentalized protein kinase A (PKA). Upon receptor initiated cAMP-mobilization, PKA regulatory subunits (R) bind cAMP thereby triggering dissociation and activation of bound PKA catalytic subunits (PKAc). Mutations in PKAc or RIa subunits manipulate PKA dynamics and activities which contribute to specific disease patterns. Mutations activating cAMP/PKA signaling contribute to carcinogenesis or hormone excess, while inactivating mutations cause hormone deficiency or resistance. Here we extended the application spectrum of a Protein-fragment Complementation Assay based on the Renilla Luciferase to determine binary protein:protein interactions (PPIs) of the PKA network. We compared time- and dose-dependent influences of cAMP-elevation on mutually exclusive PPIs of PKAc with the phosphotransferase inhibiting RIIb and RIa subunits and the protein kinase inhibitor peptide (PKI). We analyzed PKA dynamics following integration of patient mutations into PKAc and RIa. We observed that oncogenic modifications of PKAc(L206R) and RIa(Δ184-236) as well as rare disease mutations in RIa(R368X) affect complex formation of PKA and its responsiveness to cAMP elevation. With the cell-based PKA PPI reporter platform we precisely quantified the mechanistic details how inhibitory PKA interactions and defined patient mutations contribute to PKA functions.
Institute of Biochemistry and Center for Molecular Biosciences, University of Innsbruck Innsbruck, Austria.
Ruth
R
Röck
Institute of Biochemistry and Center for Molecular Biosciences, University of Innsbruck Innsbruck, Austria.
Johanna E
JE
Mayrhofer
Institute of Biochemistry and Center for Molecular Biosciences, University of Innsbruck Innsbruck, Austria.
Verena
V
Bachmann
Institute of Biochemistry and Center for Molecular Biosciences, University of Innsbruck Innsbruck, Austria.
Eduard
E
Stefan
Acrodysostosis; Carney complex; GPCR; cAMP-dependent protein kinase A; molecular interactions; patient mutations; protein-fragment complementation assay